4,5

11

113

ſij

13

, :5 2:5

Į,į

33

1,1

*****:*

ğ : 5

4:3

2:3

ļ.i.

UTILITY PATENT APPLICATION **TRANSMITTAL**

Attorney Docket No		PC10751A					
First Named	Inventor or Applic	cation Identifier	Michael J Coyne	0			
Title	A METHOD OF MEASURING THE DURATION OF ADEQUATE IMMUNE MEMORY IN COMPANION ANIMALS						

Express Mail Label No. EF321677679US (Only for new nonprovisional applications under 37C F R §1 53(b)) Assistant Commissioner for Patents APPLICATION ELEMENTS ADDRESS TO. **Box Patent Application** See MPEP chapter 600 concerning utility patent application contents Washington, DC 20231 1. *Fee Transmittal Form (e.g., PTO/SB/17) 6 Microfiche Computer Program (Appendix) (Submit an original, and a duplicate for fee processing) 7. Nucleotide and/or Amino Acid Sequence Submission 2. Specification [Total Pages 40 (if applicable, all necessary) (preferred arrangement set forth below) Descriptive title of the Invention a. Computer Readable Copy Cross References to Related Applications b. Paper Copy (identical to computer copy) Statement Regarding Fed sponsored R&D Reference in Microfiche Appendix Statement verifying identity of above copies c Background of the Invention ACCOMPANYING APPLICATION PARTS Brief Summary of the Invention Assignment Papers (cover sheet & document(s)) Brief Description of the Drawings (if filed) **Detailed Description** Power of Attorney 9 37 C.F R §3 73(b) Statement Claim(s) (when there is an assignee) Abstract of the Disclosure 10 English Translation Document (if applicable) 11 Information Disclosure Copies of IDS Drawing(s) (35 U S.C 11 3)[Total sheets Statement (IDS)/PTO-1449 Citations Oath or Declaration [Total pages 12 Preliminary Amendment Newly executed (original or copy) 13. Return Receipt Postcard (MPEP 503) (Should be specifically itemized) Copy from a prior application (37 CFR §1.63(d)) 14 *Small Entity Statement filed in prior application, (for continuation/divisional with Box 17 completed) Statement(s) Status still proper and desired [Note Box 5 below] (PTO/SB/09-12) DELETION OF INVENTOR(S) 15. Certified Copy of Priority Document(s) Signed statement attached deleting (if foreign priority is claimed) inventor(s) named in the prior application, see 37 C.F.R. §§1.63(d)(2) and 1.33(b). Incorporation By Reference (useable if Box 4b is checked) Other. Priority Claim The entire disclosure of the prior application, from which a This application claims the benefit of priority of copy of the oath or declaration is supplied under Box 4b, is U.S. Provisional Application No 60/200,041, considered to be part of the disclosure of the accompanying filed April 27, 2000. application and is hereby incorporated by reference therein. *NOTE FOR ITEMS 1 & 14: IN ORDER TO BE ENTITLED TO PAY SMALL ENTITY FEES, A SMALL ENTITY STATEMENT IS REQUIRED (37 C.F.R. § 1.27), EXCEPT IF ONE FILED IN A PRIOR APPLICATION IS RELIED UPON (37 C.F.R. § 1.28). If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment Continuation Divisional Continuation-in-part (CIP) of prior application No 60/200,041 Prior application information: Examiner Group/Art Unit CORRESPONDENCE ADDRESS 18. (Insert Customer No. or Attach bar code label here) Customer Number or Bar Code Label Correspondence address below Name Paul H. Ginsburg Address Pfizer Inc Address 235 East 42nd Street, 20th Floor City New York State New York Zip Code 10017-5755 Country United States Of America Telephone (212)573-2369 Fax (212)573-1939 NAME (Print/type) Registration No. (Attorney/Agent) Jeffrey-N. Myers 41,213 Signature Date April 19, 2001

		Complete if Known						
FEE TRANSMITTAL	Application Number				Not Yet Known			
	Filing Date				Herewith			
Patent fees are subject to annual revision on October 1. These are the fees effective October 1, 1997.		First Named Inventor			Michael J. Coyne			
Small Entity payments <u>must</u> be supported by a small entity statement, otherwise large entity fees must be paid. See Forms PTO/SB/09-12.		Examiner Name			Not Yet Assigned			
See 37 C.F.R. §§ 1.27 and 1.28.		Group/Art Unit			Not Yet Assigned			
Total Amount of Payment (\$)710.00		Attorney Docket No.			PC 10751A			
METHOD OF PAYMENT (check one)				FEE CA	LCULATION (continued)			
1. The commissioner is hereby authorized to charge	3. ADDITIO							
indicated fees and credit any over payments to: Deposit	Large Er Fee	rtity Fee	Small Fee	Entity Fee				
Account 16-1445 Number 16-1445	Code	(\$)	Code	(\$)	Fee Description Fee Paid			
Deposit Account Name Pfizer Inc	105	130	205	65	Surcharge late fee or oath			
Charge Any Additional Charge the Issue Fee Set in	127	50	227	25	Surcharge–late provisional filing fee or cover sheet			
Fee Required Under 37 C.F.R. § 1.18 at the Mailing of the Notice of Allowance.	139	130	139	130	Non-English specification			
of the Notice of Allowance.		2,520	147	2,520	For filing a request for reexamination			
Payment Enclosed:	112	920*	112	920*	Requesting publication of SIR prior to			
Check Money Order Other	113	1,840*	113	1,840*	Examiner action Requesting publication of SIR after Examiner action			
FEE CALCULATION	115	110	215	55	Extension for reply within first month			
1 BASIC FILING FEE	116	390	216	195	Extension for reply within second month			
	117	890	217	445	Extension for reply within third month			
हिंदुई Fee Fee Fee Fee Description Fee Paid Code (\$) Code (\$)	118	1,390	218	695	Extension for reply within fourth month			
194 710 201 355 Utility filing fee 710.00	128	1,890	228	945	Extension for reply within fifth month			
1.06 320 206 160 Design filing fee	119	310	219	155	Notice of Appeal			
107 490 207 245 Plant filing fee	120	310	220	155	Filing a brief in support of an appeal			
108 710 208 355 Reissue filing fee	121	270	221	135	Request for oral hearing			
र्मि 150 214 75 Provisional filing fee	138	1,510	138	1,510	Petition to institute a public use proceeding			
SUBTOTAL (1) (\$) 710.00		110	240	55	Petition to revive - unavoidable			
2. EXTRA CLAIM FEES	141	1,240	241	620	Petition to revive - unintentional			
Extra Fee from Claims below Fee Paid	142	1,240	242	620	Utility issue fee (or reissue)			
Total Claims 10 -20**= 0 X =	143	440	243	220	Design issue fee			
Independent 1 - 3**= 0 X = =	144	600	244	300	Plant issue fee			
Multiple Dependent =	122	130	122	130	Petitions to the Commissioner			
** or number previously paid, if greater; For Reissues, see below Large Entity Small Entity		50	123	50	Petitions related to provisional applications			
Fee Fee Fee Fee Description	126	240	126	240	Submission of Information Disclosure			
Code (\$) 103 18 203 9 Claims in excess of 20	581	40	581	40	Statement Recording each patent assignment per			
102 80 40 Independent claims in excess of 3	146	710	246	355	property (times number of properties) Filing a submission after final rejection			
202 104 270 204 135 Multiple dependent claim, if not paid	149	710	249	355	(37 CFR 1.129(a)) For each additional invention to be			
109 80 209 40 **Reissue independent claims over		examined (37 CFR 1.129(b)) Other Fee (specify)						
original patent 110 18 210 9 **Reissue claims in excess of 20 and over original patent	Other Fee (specify)							
SUBTOTAL (2) (\$) 0.00	*Reduced t	by Basic	Filing Fe	e Paid	SUBTOTAL (3) (\$) 0.00			
SUBMITTED BY Complete (if Applicable)								
Type or Printed Name					Reg. Number 41,213			
Signature MM Olympian	Date	April	19, 2001		Deposit Account 16-1445			

CERTIFICATE OF MAILING EXPRESS MAIL

PFIZER DOCKET NO: PC10751A

APPLICATION NUMBER: NOT YET ASSIGNED

TITLE: A METHOD OF MEASURING THE DURATION OF ADEQUATE

IMMUNE MEMORY IN COMPANION ANIMALS

APPLICANT: Michael J. Coyne, et al.

"Express Mail" mailing label number EF321677679US

Date of Deposit: April 19, 2001

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Commissioner for Patents, Box Patent Application, Washington, D.C. 20231.

Vilma Pizarro

(Signature of person mailing paper)or fee

Pfizer, Inc Patent Department, 20th Floor 235 East 42nd Street New York, NY 10017-5755 (212) 573-2896